MediciNova Posts Promising Data From COVID-19 Treatment Candidate

  • MediciNova Inc MNOV says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 patients demonstrated significant improvements compared to placebo for all four clinical endpoints analyzed. 
  • The trial achieved statistical significance for one of the co-primary endpoints, the proportion of subjects free of respiratory failure. 
  • The trial also achieved statistical significance for the proportion of subjects discharged from the hospital.
  • Related: MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking.
  • 71% of subjects in the MN-166 group and 35% of subjects in the placebo group were free of respiratory failure at Day 7.
  • 71% of subjects in the MN-166 group and 47% of subjects in the placebo group had improved clinical status.
  • 65% of subjects in the ibudilast group and 29% of subjects in the placebo group were discharged from the hospital.
  • There were two deaths in the placebo group and no deaths in the MN-166 (ibudilast) group.
  • There were no serious adverse events related to ibudilast.
  • Price Action: MNOV shares are up 8.09% at $2.54 during the premarket session on the last check Wednesday.

Posted In: BriefsCOVID-19 CoronavirusCOVID-19 VaccineBiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.